Duration of untreated psychosis and neurocognitive functioning in first-episode psychosis: A systematic review and meta-analysis

K Allott; D Fraguas; CF Bartholomeusz; CM Díaz-Caneja; C Wannan; EM Parrish; GP Amminger; C Pantelis; C Arango; PD McGorry; M Rapado-Castro

Journal article

Duration of untreated psychosis and neurocognitive functioning in first-episode psychosis: A systematic review and meta-analysis

K Allott, D Fraguas, CF Bartholomeusz, CM Díaz-Caneja, C Wannan, EM Parrish, GP Amminger, C Pantelis, C Arango, PD McGorry, M Rapado-Castro

Psychological Medicine | CAMBRIDGE UNIV PRESS | Published : 2018

DOI: 10.1017/S0033291717003002

Abstract

Background: Previous reviews suggest there is minimal evidence for an association between duration of untreated psychosis (DUP) and neurocognition. This is based on tallied findings of studies with small samples and neurocognition viewed as a single construct. We aimed to conduct a systematic review and meta-analysis examining the association between DUP and individual neurocognitive domains and tests in first-episode psychosis (FEP). Method: MOOSE and PRISMA guidelines were followed. Forty-three studies involving 4647 FEP patients were included. For studies providing correlations between DUP and neurocognition, 12 separate meta-analyses were performed based on neurocognitive domains/indices..

View full abstract

University of Melbourne Researchers

Kelly Allott Author

Cali Bartholomeusz Author

Cassandra Wannan Author

Paul Amminger Author

Related Projects (2)

RESEARCH FELLOWSHIP - PROF CHRISTOS PANTELIS

I have established and head the Melbourne Neuropsychiatry Centre within the University of Melbourne. My university position is a research ch..

NEUROBIOLOGICAL 'RISK' AND 'RESILIENCE' BIOMARKERS OF SEVERE MENTAL ILLNESS

Mental disorders of childhood (schizotypal disorder, autism spectrum disorders) and adolescence (psychoses, schizophrenia) represent a major..

Grants

Awarded by European Commission

Funding Acknowledgements

This work was supported by a Ronald Philip Griffiths Fellowship from the Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne awarded to KA. MR-C was supported by a Sara Borrell Health Research Fellowship from the Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III, an Alicia Koplowitz Research Grant, an Alicia Koplowitz Short-Term Visiting Fellowship from the Alicia Koplowitz Foundation, an IiSGM Fellowship Award for Short-Term Placements from the Health Research Institute from the Hospital Gregorio Maranon (IiSGM) (Madrid, Spain) and a NARSAD independent investigator Grant (#24628) from the Brain & Behavior Research Foundation. DF, CMD-C, MR-C and CA were supported by the Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III, co-financed by ERDF Funds from the European Commission, 'A way of making Europe', CIBERSAM, Madrid Regional Government (S2010/BMD-2422 AGES), European Union Structural Funds and European Union Seventh Framework Programme under grant agreements FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7-HEALTH-2009-2.2.1-3-242114 (Project OPTiMISE), FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY); Fundacion Alicia Koplowitz and Fundacion Mutua Madrilena, and ERA-NET NEURON (Network of European Funding for Neuroscience Research). CMD-C has previously held a 'Rio Hortega' fellowship from the Instituto de Salud Carlos III and an Alicia Koplowitz Short-Term Visiting Fellowship from the Alicia Koplowitz Foundation. CP was supported by a NHMRC Senior Principal Research Fellowship (#628386; 1105825).